Live symbol workspace

BIIB market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $172.97

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$164.32

Resistance

$181.62

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$172.97

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 6 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

BIIB News Intelligence (3 articles)

AI-curated news influencing BIIB price, sentiment, and trend

Explore All BIIB News with AI Analysis

Economy

1 month, 3 weeks ago

Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman)

Biogen, TE Connectivity and ZTO Express gain attention as broker upgrades and solid earnings growth position them for potential upside …

Impact on BIIB: The broker upgrades and solid earnings growth of Biogen, TE Connectivity, and …

Biogen, TE Connectivity, and ZTO Express (Cayman) are poised for potential upside due to broker … High (80%)

View full analysis →

Yahoo Finance 80% confidence

Economy

2 months, 1 week ago

Why Biogen Stock Sank While the Market Soared on Thursday

It's reaching into its coffers for a $5.6 billion acquisition.

Impact on BIIB: Biogen's stock price sank due to the $5.6 billion acquisition announcement, potentially …

Biogen's announcement of a $5.6 billion acquisition led to a decline in its stock price … High (80%)

View full analysis →

Yahoo Finance 80% confidence

Stocks

2 months, 1 week ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for …

Impact on BIIB: The acquisition is likely to have a positive impact on Biogen's stock …

Biogen is acquiring Apellis Pharmaceuticals for $5.6 billion to expand its presence in kidney disease … High (80%)

View full analysis →

MarketWatch 80% confidence